AGM Trading & Strategic Update
capAI plc is transitioning multiple platforms into live user availability, with Game42, Movie42, and Author42 scheduled for launch this week or soon. The company is moving into a phase of user adoption, iterative improvement, and commercial evaluation for these products. capAI continues to progress its capMedical initiative, focusing on AI-enabled longevity and healthcare applications, while maintaining a disciplined venture structure through Licence and Option Agreements to explore opportunities at low cost. The board believes these developments position capAI for its next growth phase, emphasizing disciplined execution and capital efficiency.
Select text to share a quote on X · sign in to keep highlights & notes in your CPAI notes
capAI plc (LSE: CPAI, OTCQB: CPIQF) is pleased to provide a trading and strategic update ahead of its Annual General Meeting to be held today, Tuesday 21st April 2026.
The Company reports continued strong execution across its platform portfolio and is now entering a key inflection point, with multiple products transitioning from development into live user availability.
Near-Term Product Launches and Platform Momentum
- Game42 (Going Live): Game42, the generative game creation platform, is scheduled to go live this week. Game42 enables users to transform inputs ranging from short prompts to full-length books into interactive game experiences, significantly lowering the barrier to game development and supporting scalable user-generated content ecosystems.
- Creator42 / Movie42 (Going Live): Creator42, previously referenced in earlier communications, will launch this week under the name Movie42. The platform converts inputs-from a few lines to long-form narratives-into cinematic, trailer-style video outputs, positioning capAI within the rapidly expanding AI-driven content creation market.
- Author42 (Hard Launch): The Company is progressing toward the hard launch of Author42, its AI-native writing platform. Author42 now includes expanded capabilities across fiction and memoir writing, alongside advanced editing and refinement tools, supporting end-to-end content creation and complementing the broader Game42 and Movie42 ecosystem.
Transition to Deployment and Commercial Evaluation
With Game42 and Movie42 entering live deployment, capAI is transitioning into a phase focused on user adoption, iterative improvement and commercial evaluation. These launches represent a significant step toward validating product-market fit across multiple verticals.
capMedical - Longevity and Healthcare Initiatives
Further to the Company's previous RNS announcements, capAI continues to progress its capMedical initiative, including its focus on AI-enabled longevity and healthcare applications. A number of potential programmes in this area remain under active evaluation, with the Company applying its disciplined venture approach to assess both scientific and commercial viability before committing further resources.
Disciplined Venture Structure (LOA Framework)
The Company has to date operated a disciplined venture model, typically securing opportunities through Licence and Option Agreements (LOAs) that provide optionality to acquire or license technologies developed in collaboration with R42.
This structure enables capAI to explore and develop multiple initiatives at relatively low cost, while retaining the ability to capture significant upside through option-based access to successful projects. By deferring major capital commitments until technical and commercial viability is clearer, the Company maintains capital discipline and reduces downside risk. However, shareholders should note that there can be no guarantee that the Company will ultimately exercise any option to acquire or license such projects. Decisions to proceed are made selectively, based on technical progress, market potential and capital allocation considerations.
Outlook
The capAI board believes that the transition of multiple platforms into live availability, combined with a growing pipeline of opportunities under evaluation, positions capAI for its next phase of growth. The Company remains focused on disciplined execution, capital efficiency and the selective advancement of high-potential initiatives.
Further updates will be provided in due course.
Commenting, Professor Ronjon Nag, Executive Chairman of capAI, said:
"We are now seeing the transition of our core platforms from development into live deployment, which is a critical step in validating both their technical capability and commercial potential.
"At the same time, we continue to apply our disciplined venture approach to the evaluation of new opportunities, including in AI-enabled longevity and healthcare, where we believe there is significant long-term value creation potential. We look forward to providing further updates as these initiatives progress."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.